(Q39221819)

English

MUC20 overexpression predicts poor prognosis and enhances EGF-induced malignant phenotypes via activation of the EGFR-STAT3 pathway in endometrial cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 September 2017

MUC20 overexpression predicts poor prognosis and enhances EGF-induced malignant phenotypes via activation of the EGFR-STAT3 pathway in endometrial cancer (English)

1 reference

Europe PubMed Central

10 September 2017

1 reference

based on heuristic

inferred from title

author name string

Chi-Hau Chen

1

1 reference

Europe PubMed Central

10 September 2017

Shu-Wei Wang

2

1 reference

Europe PubMed Central

10 September 2017

Chih-Wei Chen

3

1 reference

Europe PubMed Central

10 September 2017

Miao-Ruei Huang

4

1 reference

Europe PubMed Central

10 September 2017

Ji-Shiang Hung

5

1 reference

Europe PubMed Central

10 September 2017

Hsiu-Chin Huang

6

1 reference

Europe PubMed Central

10 September 2017

Ho-Hsiung Lin

7

1 reference

Europe PubMed Central

10 September 2017

Ruey-Jien Chen

8

1 reference

Europe PubMed Central

10 September 2017

Ming-Kwang Shyu

9

1 reference

Europe PubMed Central

10 September 2017

Min-Chuan Huang

10

1 reference

Europe PubMed Central

10 September 2017

language of work or name

0 references

publication date

19 December 2012

1 reference

Europe PubMed Central

10 September 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

10 September 2017

128

1 reference

Europe PubMed Central

10 September 2017

3

1 reference

Europe PubMed Central

10 September 2017

560-567

1 reference

Europe PubMed Central

10 September 2017

Management of recurrent endometrioid endometrial carcinoma: an overview

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Endometrial cancer state of the science meeting.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Systemic therapy for recurrent endometrial cancer: a review of North American trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Mucins in cancer: function, prognosis and therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Cell surface-associated mucins in signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Circulating KL-6/MUC1 mucin carrying sialyl Lewisa oligosaccharide is an independent prognostic factor in patients with lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Mucin 15 is expressed in human placenta and suppresses invasion of trophoblast-like cells in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

MUC1 Expression Is Increased During Human Placental Development and Suppresses Trophoblast-Like Cell Invasion In Vitro1

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Expression and functions of transmembrane mucin MUC13 in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Overexpression of MUC15 activates extracellular signal-regulated kinase 1/2 and promotes the oncogenic potential of human colon cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Molecular Cloning, Genomic Structure, and Expression Analysis of MUC20, a Novel Mucin Protein, Up-regulated in Injured Kidney

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

MUC20 suppresses the hepatocyte growth factor-induced Grb2-Ras pathway by binding to a multifunctional docking site of met

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Clinical implications of the mechanism of epidermal growth factor receptor inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Stats: transcriptional control and biological impact

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Stat proteins and oncogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

The STATs of cancer--new molecular targets come of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

B4GALNT3 expression predicts a favorable prognosis and suppresses cell migration and invasion via β₁ integrin signaling in neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

C2GnT-M is downregulated in colorectal cancer and its re-expression causes growth inhibition of colon cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR downstream pathways in pancreatic cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

MUC1 regulates nuclear localization and function of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Emerging therapeutic targets in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

STATs in cancer inflammation and immunity: a leading role for STAT3

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Two pathogenetic types of endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Molecular and pathologic aspects of endometrial carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Gefitinib--a novel targeted approach to treating cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

STAT3 as a central regulator of tumor metastases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

STAT3alpha is oncogenic for endometrial carcinoma cells and mediates the oncogenic effects of autocrine human growth hormone.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Stat3 activation in human endometrial and cervical cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Interleukin 11 regulates endometrial cancer cell adhesion and migration via STAT3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Patterns of episialin/MUC1 expression in endometrial carcinomas and prognostic relevance

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Differential expression of MUC genes in endometrial and cervical tissues and tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

The mucin expression profile of endometrial carcinoma and correlation with clinical-pathologic parameters

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.012

7 January 2021

Identifiers

10.1016/J.YGYNO.2012.12.012

1 reference

Europe PubMed Central

10 September 2017

1 reference

Europe PubMed Central

10 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39221819&oldid=2088744222"